InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Lantern Pharma Inc.

LTRN Clue Score41
United States Fiscal year ends December CIK 0001763950
$0.81 -2.08% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.81 −92.40% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 11 Jun 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Net income−2.4Fiscal year 2020Net income−5.9Fiscal year 2021Operating income−12.6Net income−12.4Fiscal year 2022Operating income−14.4Net income−14.3EPS, diluted−1.31Fiscal year 2023Operating income−17.9Net income−16.0EPS, diluted−1.47Fiscal year 2024Operating income−22.2Net income−20.8EPS, diluted−1.93Fiscal year 2025Operating income−18.0Net income−17.1EPS, diluted−1.57
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income n/a n/a −12.6 −14.4 −17.9 −22.2 −18.0
Net income −2.4 −5.9 −12.4 −14.3 −16.0 −20.8 −17.1
Growth
EPS, diluted n/a n/a n/a −1.31 −1.47 −1.93 −1.57
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−2.1Fiscal year 2020Operating cash flow−5.7Fiscal year 2021Operating cash flow−10.6Capital expenditure−0.0Free cash flow−10.6Buybacks−0.9Fiscal year 2022Operating cash flow−12.8Capital expenditure−0.0Free cash flow−12.8Buybacks−2.5Fiscal year 2023Operating cash flow−14.3Capital expenditure−0.0Free cash flow−14.4Buybacks−0.5Fiscal year 2024Operating cash flow−17.8Capital expenditure−0.0Free cash flow−17.8Fiscal year 2025Operating cash flow−15.7Capital expenditure−0.0Free cash flow−15.7
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −2.1 −5.7 −10.6 −12.8 −14.3 −17.8 −15.7
Capital expenditure n/a n/a −0.0 −0.0 −0.0 −0.0 −0.0
Free cash flow n/a n/a −10.6 −12.8 −14.4 −17.8 −15.7
Growth
Buybacks n/a n/a −0.9 −2.5 −0.5 n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash1.2Shareholders’ equity0.9Fiscal year 2020Cash19.2Shareholders’ equity19.7Fiscal year 2021Cash51.5Shareholders’ equity71.6Fiscal year 2022Cash37.2Shareholders’ equity56.0Fiscal year 2023Cash21.9Shareholders’ equity40.9Fiscal year 2024Cash7.5Shareholders’ equity21.2Fiscal year 2025Cash4.4Shareholders’ equity6.5
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 1.2 19.2 51.5 37.2 21.9 7.5 4.4
Shareholders’ equity 0.9 19.7 71.6 56.0 40.9 21.2 6.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a 2.2 7.6 8.6 11.9 16.1 11.5
1.5 3.7 5.0 5.8 6.0 6.1 6.5
n/a n/a −12.6 −14.4 −17.9 −22.2 −18.0
Growth
−2.4 −5.9 −12.4 −14.3 −16.0 −20.8 −17.1
Growth
Per share
n/a n/a −1.13 −1.31 −1.47 −1.93 −1.57
n/a n/a n/a −1.31 −1.47 −1.93 −1.57
Growth
n/a n/a 10.9 10.9 10.8 10.8 10.9
n/a n/a n/a 10.9 10.8 10.8 10.9
Growth −0.1% −0.7% +1.3%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.